Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance - PubMed (original) (raw)
Review
Chromosome 17 abnormalities and inactivation of the p53 gene in chronic myeloid leukemia and their prognostic significance
H Nakai et al. Leuk Lymphoma. 1995 Oct.
Abstract
We have reviewed all the relevant studies on the loss of the short arm of chromosome 17 (17p) and inactivation of the p53 gene in chronic myelogenous leukemia (CML) in an attempt to clarify their roles in the progression of CML. Loss of a 17p (hemizygous 17p) and p53 inactivation emerged as the disease progressed and were closely associated with each other. About half of the cases with loss of a 17p, however, did not show p53 inactivation. In these cases loss of a 17p preceded p53 inactivation, which suggested that either reduction of the p53 gene dosage or inactivation of another tumor-suppressor gene on 17p might contribute to the disease progression. Both loss of a 17p and p53 inactivation may serve as poor prognostic factors but the prognostic significance of the former only emerged when metaphase cells with loss of a 17p were dominant amongst the total cell population analyzed.
Similar articles
- Prognostic significance of loss of a chromosome 17p and p53 gene mutations in blast crisis of chronic myelogenous leukaemia.
Nakai H, Misawa S, Taniwaki M, Horiike S, Takashima T, Seriu T, Nakagawa H, Fujii H, Shimazaki C, Maruo N, et al. Nakai H, et al. Br J Haematol. 1994 Jun;87(2):425-7. doi: 10.1111/j.1365-2141.1994.tb04938.x. Br J Haematol. 1994. PMID: 7947294 - Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.
Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K. Nakai H, et al. Cancer Res. 1992 Dec 1;52(23):6588-93. Cancer Res. 1992. PMID: 1423304 - Analysis of the p53 gene in myeloid malignancies associated with chromosomal abnormalities involving the short arm of chromosome 17.
Rege-Cambrin G, Gaidano G, Serra A, Scaravaglio P, Guglielmelli T, Guerrasio A, Giovinazzo B, Saglio G. Rege-Cambrin G, et al. Leukemia. 1994 Apr;8 Suppl 1:S23-6. Leukemia. 1994. PMID: 8152298 - Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis.
Di Bacco A, Keeshan K, McKenna SL, Cotter TG. Di Bacco A, et al. Oncologist. 2000;5(5):405-15. doi: 10.1634/theoncologist.5-5-405. Oncologist. 2000. PMID: 11040277 Review. - Molecular mechanisms in the evolution of chronic myelocytic leukemia.
Cline MJ, Jat PS, Foti A. Cline MJ, et al. Leuk Lymphoma. 1992 Jul;7(4):283-7. doi: 10.3109/10428199209049779. Leuk Lymphoma. 1992. PMID: 1493427 Review.
Cited by
- FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5.
Takeda K, Ohta S, Nagao M, Kobayashi E, Tago K, Funakoshi-Tago M. Takeda K, et al. Int J Mol Sci. 2024 Mar 26;25(7):3693. doi: 10.3390/ijms25073693. Int J Mol Sci. 2024. PMID: 38612503 Free PMC article. - Integrated genomic sequencing in myeloid blast crisis chronic myeloid leukemia (MBC-CML), identified potentially important findings in the context of leukemogenesis model.
Kazemi-Sefat GE, Keramatipour M, Vaezi M, Razavi SM, Kavousi K, Talebi A, Rostami S, Yaghmaie M, Chahardouli B, Talebi S, Mousavizadeh K. Kazemi-Sefat GE, et al. Sci Rep. 2022 Jul 27;12(1):12816. doi: 10.1038/s41598-022-17232-w. Sci Rep. 2022. PMID: 35896598 Free PMC article. - Prognostic significance of isochromosome 17q in hematologic malignancies.
Koczkodaj D, Muzyka-Kasietczuk J, Chocholska S, Podhorecka M. Koczkodaj D, et al. Oncotarget. 2021 Mar 30;12(7):708-718. doi: 10.18632/oncotarget.27914. eCollection 2021 Mar 30. Oncotarget. 2021. PMID: 33868591 Free PMC article. - SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. Nowak D, et al. Blood. 2010 Feb 4;115(5):1049-53. doi: 10.1182/blood-2009-03-210377. Epub 2009 Dec 2. Blood. 2010. PMID: 19965645 Free PMC article. - Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Wendel HG, de Stanchina E, Cepero E, Ray S, Emig M, Fridman JS, Veach DR, Bornmann WG, Clarkson B, McCombie WR, Kogan SC, Hochhaus A, Lowe SW. Wendel HG, et al. Proc Natl Acad Sci U S A. 2006 May 9;103(19):7444-9. doi: 10.1073/pnas.0602402103. Epub 2006 May 1. Proc Natl Acad Sci U S A. 2006. PMID: 16651519 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous